Incretin-based Drugs and Pancreatic Cancer

What this study is testing ClinicalTrials.gov NCT02475499 ↗

Description as written by the study sponsor.

The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer (PC) compared to sulfonylureas. The investigators will carry out separate population based cohort studies using administrative health databases in five jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for PC. The results from the separate sites will be combined to provide an overall assessment of the risk of PC in users of incretin-based drugs and by class of incretin-based drugs.

Treatments tested

• DPP-4 inhibitors also known as incretin-based drugs, sitagliptin, vildagliptin, saxagliptin Drug

  Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

• GLP-1 analogs also known as incretin-based drugs, exenatide, liraglutide Drug

  Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

• Sulfonylureas also known as oral hypoglycemic agent, glibenclamide, chlorpropamide, tolbutamide, glibornuride, tolazamide, carbutamide, glipizide, gliquidone, gliclazide, metahexamide, glisoxepide, glimepiride, acetohexamide, glymidine Drug

  Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

• Biguanides also known as oral hypoglycemic agent, phenformin, metformin, buformin Drug

  Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

• Thiazolidinediones also known as oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone Drug

  Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

• Alpha-glucosidase inhibitors also known as oral hypoglycemic agent, acarbose, miglitol, voglibose Drug

  Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.

• Meglitinides also known as oral hypoglycemic agent, repaglinide, nateglinide Drug

  Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.